Press Releases
Trading Update: Profitability for full year 2020 expected to be ahead of market expectations
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that, despite COVID-19, it is achieving stronger than anticipated growth across the second half of the year. The Company is benefiting from continued operational leverage, generated by revenue growth and investments made to drive scale and efficiency.
Read more
Investor Presentation: 25th August
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it will provide a live presentation presented by CEO, Giulio Cerroni and CFO, Grant Nash, on Tuesday 25 August at 1. 30pm.
Read more
IXICO to present at the On Helix Digital conference
IXICO plc announces the Company’s digital attendance at the On Helix Digital conference, on the 13-14 July 2020. IXICO will share a pre-recorded presentation by Robin Wolz, SVP Science & Innovation, titled ‘Biomarkers for CNS clinical trials from imaging and actigraphy.
Read more
Expected strengthening FY20 financial performance of at least £9.1m revenues, £0.9m EBITDA and positive operating cash
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces a trading update, confirming that the impact of COVID-19 has been modest and that IXICO expects to maintain double-digit revenue growth across FY21.
Read more
Half yearly report to 31 March 2020
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces its unaudited interim results for the six months ended 31 March 2020. Financial highlights: · Reported revenues of £4. 6 million; 33. 0% growth on H1 2019 (2019: £3. 4 million) · Strong gross margin at 66. 5% (2019: 66.
Read more
Support free cabs for NHS workers
To help relieve the pressure on NHS staff travelling to and from hospitals minicabit , a nationwide cab booking service, will provide through up to 800 cab companies free cab services to NHS staff. They will engage 25,000 drivers and make as many available as possible. THE NEED IS URGENT.
Read more
£10.5m contract win, trading update for the period ended 31 March 2020, and the potential impact of COVID-19
New contract win: IXICO plc (AIM: IXI) is pleased to announce today the signing of a substantial new contract for a late-phase open label study in Huntington's disease (HD). The four-year contract runs to 2024 with a total value of £10.
Read more
IXICO's Response to Novel Coronavirus (COVID-19) - Update
20 March 2020: IXICO Response to Novel Coronavirus (COVID-19) - Update Dear Valued Client and Partners Earlier this week the UK government updated its guidance in response to the COVID-19 pandemic (as of 16 March), to escalate social distancing measures and minimise the need for non-essential travel.
Read more1-8 of 28 results